Stockreport

Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights [Yahoo! Finance]

Arcellx, Inc.  (ACLX) 
PDF RRMM which demonstrated 97% ORR and 62% CR/sCR at a median follow-up of 9.5 months -- -- No delayed neurotoxicities observed with anito-cel, including no Parkinsonism, [Read more]